U.S. Markets closed
  • S&P 500

    3,635.41
    +57.82 (+1.62%)
     
  • Dow 30

    30,046.24
    +454.97 (+1.54%)
     
  • Nasdaq

    12,036.79
    +156.15 (+1.31%)
     
  • Russell 2000

    1,853.53
    +35.23 (+1.94%)
     
  • Crude Oil

    44.80
    -0.11 (-0.24%)
     
  • Gold

    1,806.10
    +1.50 (+0.08%)
     
  • Silver

    23.32
    +0.02 (+0.09%)
     
  • EUR/USD

    1.1908
    +0.0011 (+0.0953%)
     
  • 10-Yr Bond

    0.8820
    +0.0250 (+2.92%)
     
  • Vix

    21.64
    -1.02 (-4.50%)
     
  • GBP/USD

    1.3364
    +0.0005 (+0.0401%)
     
  • USD/JPY

    104.4860
    +0.0060 (+0.0057%)
     
  • BTC-USD

    19,120.31
    0.00 (0.00%)
     
  • CMC Crypto 200

    377.31
    +7.56 (+2.04%)
     
  • FTSE 100

    6,432.17
    +98.33 (+1.55%)
     
  • Nikkei 225

    26,485.30
    +319.71 (+1.22%)
     

Seres Therapeutics to Present at the Cowen 2020 Health Care Conference

·1 min read

Seres Therapeutics, Inc. (NASDAQ: MCRB) today announced that it will present at the Cowen 2020 Health Care Conference in Boston, Mass. on Monday, March 2 at 1:30 p.m. ET.

A live audio webcast of the presentation will be available under the "Investors and Media" section of Seres’ website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres’ SER-287 program has obtained Fast Track and Orphan Drug designation from the U.S. Food and Drug Administration and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres’ SER-109 program has obtained Breakthrough Therapy and Orphan Drug designations from the FDA and is in Phase 3 development for recurrent C. difficile infection. Seres is also developing SER-401 in a Phase 1b study in patients with metastatic melanoma. SER-301, a next-generation, rationally-designed, live microbiome therapeutic candidate is in preclinical development for ulcerative colitis. For more information, please visit www.serestherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200225005233/en/

Contacts

Carlo Tanzi, Ph.D., 617-203-3467
ctanzi@serestherapeutics.com